Eli Lilly prepares obesity efforts with future hope – goes down same path as Novo Nordisk
US Eli Lilly is testing its weight loss and glucose control drug candidate Tirzepatide, joining Novo Nordisk on the obesity market for the first time. The road to commercialization will look a lot like that of Novo Nordisk, says Eli Lilly executive.
BY KEVIN GRØNNEMANN, TRANSLATED BY NIELSINE NIELSEN
Ever since Novo Nordisk entered the obesity market in 2015, its management and investors have hoped for another pharmaceutical firm to accompany it and help establishing and focusing on the market for relevant treatments.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
